GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
GenSight Biologics's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases.
GenSight was founded in 2013. The company is headquartered in Paris, Ile-de-France, France with an additional office in New York, New York.
GenSight has been using an integrated development platform based on the combination of a gene therapy-based approach with technologies such as Mitochondrial Target Sequence (MTS) and optogenetics.
GenSight Biologics's lead product candidate, GS010, is in Phase III trials in Leberâ's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults.
GenSight is venture backed by Index Ventures, Novartis Venture Fund, Abingworth, & Versant Ventures among others. The company went public on Jul 22, 2016 with a €237.4M IPO valuation.